ALS Expert Mary Sedarous is Hopeful for FDA-Approved Radicava
SEPTEMBER 22, 2017
Mary Sedarous, M.D.
Mary Sedarous, M.D., is a neurologist and a neuromuscular physician who serves as the Medical Director of the ALS Clinic at Hackensack Meridian Hospital in New Jersey, and the Robert Wood Johnson Medical Student Site Director for Neurology Clerkship at the Jersey Shore University Medical Center.
In this video, she discusses Radicava, the importance of new data that will be available now that more patients have access to the drug, and why the approval is already a success.
Sedarous: So, before Radicava, we had only Ryloteck; it was the only other FDA-approved medication that had an effect in slowing the progression down of the disease. It wasn’t until 22 years after Rylozole was out in the market that Radicava was introduced. So, Radicava has been out in Japan for a while. It’s a free radical scavenger, and it’s been used in the context of stroke treatment and recently ALS related clinical trials have been conducted in Japan showing that there might be some benefit to slowing down the progression.
The research has shown that there is definitely oxidative stress, and that is when you have free radicals of oxygen that can be dangerous to cells, that has been indicated in the progression of the disease. Radicava lessens the free radical oxidative stress, hopefully thereby providing some delays in the progression of the disease, and that is what the clinical trials have shown.
It is a success in and of itself that 22 years later, we have another drug, and we’re hopeful that it shows benefit in more than just what has already been tested. It’s been shown to show improvement in patients with a relatively early diagnosis of ALS. We will find out, now that we will have access to it in all of our ALS patients, what benefits it has to patients outside of that group.
For the latest videos with information from experts within the rare disease community, follow Rare Disease Report on Facebook and Twitter.